Clinical Trials Logo

Tardive Dyskinesia clinical trials

View clinical trials related to Tardive Dyskinesia.

Filter by:

NCT ID: NCT06218719 Not yet recruiting - Tardive Dyskinesia Clinical Trials

Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients

Start date: February 2025
Phase:
Study type: Observational

The statistical analysis of the collected data aims to reveal the many factors that influence patient involvement in clinical trials. Findings will be disseminated through conferences and scholarly papers to benefit all parties participating in clinical trials. These findings will help to shape the design of future clinical trials for people with tardive dyskinesia, as well as enhance recruiting techniques and retention rates.

NCT ID: NCT06216054 Recruiting - Huntington Disease Clinical Trials

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Start date: December 23, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for later clinical trials.

NCT ID: NCT06107829 Not yet recruiting - Clinical trials for Intellectual Disability

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

TD-AIDD
Start date: March 2024
Phase: Phase 4
Study type: Interventional

The goal of this open-label clinical trial is to test the safety and efficacy of valbenazine treatment in patients with Intellectual/Developmental Disability (IDD) who have a diagnosis of Tardive dyskinesia (TD). The main questions this study aims to answer are: - Does valbenazine treatment of TD in the previously untreated patient population of adults with IDD produce comparable amelioration of signs of movement disorder as what has historically been reported in adults without IDD? - Is valbenazine treatment of TD in persons with IDD as safe as what has historically been reported in adults without IDD? - Does valbenazine treatment improve Quality of Life (QOL) in persons with IDD and TD treated with valbenazine? - Does valbenazine treatment produce positive change in Activities of Daily Living (ADLs) in persons with IDD and TD? - Does valbenazine treatment of TD in persons with IDD reduce caregiver burden? In this study, 25 participants with IDD and TD will undergo valbenazine treatment for 24 weeks. The participants will be seen for a total of 5 visits: at baseline, and at follow up visits at 3 weeks, 6 weeks, 12 weeks, and 24 weeks. This study does not include a comparison group. Therefore, researchers will compare the response of the study participants to valbenazine treatment with those from a previous reported work that resulted in the FDA approval of this medication.

NCT ID: NCT06011408 Recruiting - Tardive Dyskinesia Clinical Trials

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

Start date: May 30, 2023
Phase: N/A
Study type: Interventional

The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.

NCT ID: NCT05859698 Recruiting - Schizophrenia Clinical Trials

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Start date: May 25, 2023
Phase: Phase 4
Study type: Interventional

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

NCT ID: NCT05238701 Completed - Huntington Disease Clinical Trials

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Start date: February 25, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.

NCT ID: NCT05053321 Not yet recruiting - Tardive Dyskinesia Clinical Trials

Reduction of Demoralization After Treatment of TD With Valbenazine

Start date: April 2024
Phase: Phase 1
Study type: Interventional

The purpose of this research project is to determine the feasibility of a larger study aimed at demonstrating that treatment of tardive dyskinesia with Valbenazine is associated with reduction of demoralization

NCT ID: NCT04794413 Completed - Tourette Syndrome Clinical Trials

Pimavanserin Treatment in TS

Start date: November 12, 2018
Phase: Early Phase 1
Study type: Interventional

This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome. Pimavanserin is an investigational drug for Tourette Syndrome, which means it has not been approved by the United States Food and Drug Administration (FDA) to treat Tourette Syndrome. Pimavanserin has been approved by the FDA as a treatment for hallucinations in Parkinson's Disease. It is currently marketed under the name NUPLAZID (pimavanserin) capsules by Acadia Pharmaceuticals.

NCT ID: NCT03891862 Completed - Clinical trials for Tardive Dyskinesia (TD)

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Start date: March 18, 2019
Phase: Phase 4
Study type: Interventional

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.

NCT ID: NCT03698331 Completed - Clinical trials for Tardive Dyskinesia (TD)

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Start date: September 14, 2018
Phase: Phase 4
Study type: Interventional

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.